Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL.
Ariel PerezGrace JohnsonKedar PatelBrian ArciolaAnthony WoodChristina A BachmeierJulio C ChavezBijal D ShahFarhad KhimaniTaiga NishihoriAleksander LazaryanMarco L DavilaRahul MhaskarFrederick L LockeSameh GaballaMichael D JainPublished in: Blood advances (2022)